Literature DB >> 31237145

Excess of second tumors in denosumab-treated patients: a metabolic hypothesis.

Valeria Tovazzi1, Alberto Dalla Volta2, Rebecca Pedersini1, Vito Amoroso1, Alfredo Berruti1.   

Abstract

Entities:  

Keywords:  denosumab; hyperparathyroidism; hypocalcemia; second malignancies

Year:  2019        PMID： 31237145     DOI： 10.2217/fon-2019-0170

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


× No keyword cloud information.
  3 in total

1.  Safety and efficacy of extended dosing intervals of denosumab in patients with solid cancers and bone metastases: a retrospective study.

Authors:  Aseala I Abousaud; Meagan S Barbee; Christine C Davis; Sarah E Caulfield; Zeyuan Wang; Alexa Boykin; Bradley C Carthon; Keerthi Gogineni
Journal:  Ther Adv Med Oncol       Date:  2020-12-23       Impact factor: 8.168

Review 2.  Osteosarcoma mechanobiology and therapeutic targets.

Authors:  Zunaira Shoaib; Timothy M Fan; Joseph M K Irudayaraj
Journal:  Br J Pharmacol       Date:  2021-12-21       Impact factor: 9.473

Review 3.  MDA-9/Syntenin (SDCBP): Novel gene and therapeutic target for cancer metastasis.

Authors:  Swadesh K Das; Santanu Maji; Stephen L Wechman; Praveen Bhoopathi; Anjan K Pradhan; Sarmistha Talukdar; Devanand Sarkar; Joseph Landry; Chunqing Guo; Xiang-Yang Wang; Webster K Cavenee; Luni Emdad; Paul B Fisher
Journal:  Pharmacol Res       Date:  2020-02-13       Impact factor: 7.658
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.